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Purpose: Lung cancer remains the leading cause of cancer death in
both men and women. A substantial number of patients with early
stage non-small cell lung cancer (NSCLC) are unfit for standard surgery
due to cardiopulmonary dysfunction and/or other comorbidity. The
appropriate management for this population has not been defined.
Methods: Retrospective analysis of patients with clinical stage I
NSCLC judged to be unsuitable for lobectomy between 1996 and 2005.
Results: Ninety-six patients, representing 23% of all patients treated
for clinical stage I NSCLC were included in this analysis. The
median age was 73 years and most patients were female. Patients
underwent limited resection (LR, n  45), primary radiotherapy
(RT, n  39) or radiofrequency ablation (n  12). With median
follow-up of 30 months, 61 patients remain alive. Actuarial 3-year
survival is 65% following LR and 60% after primary RT. Local
tumor relapse and distant metastases were observed with approxi-
mate equal probability following either LR or RT.
Conclusion: Medical inoperability does not necessarily correspond
to poor survival in patients with early stage NSCLC. A nihilistic
approach is not warranted towards this population, and prospective
trials are needed to better define optimal treatment strategies.
Key Words: Stage I, Medically inoperable, Non-small cell lung
cancer, Radiotherapy.
(J Thorac Oncol. 2009;4: 69–73)
Lobectomy is the standard of care for patients with Stage Inon-small cell lung cancer (NSCLC), as it offers an
excellent chance at long term survival.1 However, a signifi-
cant subset of patients are at high risk for perioperative
morbidity and mortality due to comorbid conditions.2 There
is no established standard of care for this patient population.
In the absence of prospective randomized studies, many
different strategies are offered to patients who are “medically
inoperable.” Sublobar resection and thoracoscopic surgical
techniques have been used to spare lung parenchyma in
patients with a low predicted postlobectomy pulmonary func-
tion and to improve recovery times.3–6 A Cochrane Database
review analyzed 26 nonrandomized studies using primary
external beam radiotherapy in this population with a variety
of techniques. Authors reported an overall survival of 17 to
55% at 3 years.7 Percutaneous radiofrequency ablation (RFA)
has also been used. A recent review of current series in the
literature lists a range of reported 3 year overall survival rates
of 15 to 46%.8 Despite the emergence of these approaches for
the treatment of high-risk patients with early stage NSCLC,
many patients with comorbid medical illness receive no
cancer directed therapy.9 The intent of this review is to
evaluate our recent experience in the treatment of this patient
population.
PATIENTS AND METHODS
This retrospective review included patients with Amer-
ican Joint Committee on Cancer clinical stage IA or IB
NSCLC evaluated at the State University of New York
Upstate Medical University between 1996 and 2005. Patients
treated with standard surgery (e.g., lobectomy or pneumonec-
tomy) were excluded from this analysis. Patients were iden-
tified though the institutional tumor registry, and the study
was approved by the institutional review board. A histolog-
ically confirmed diagnosis of NSCLC was necessary for
inclusion in this study. All patients had a staging with
computed tomographic (CT) imaging and were given an
initial clinical stage per American Joint Committee on Cancer
staging criteria.10 Positron emission tomography was not in
routine use for NSCLC staging during the entire study period
at our institution. Therefore, the majority of patients did not
receive pretreatment positron emission tomography. Data
recorded included patient age, sex, comorbid conditions,
prior malignancies, oxygen requirements, clinical stage, tu-
mor size and location, histology, grade, performance status,
pre- and posttreatment forced expiratory volume in 1 second
(FEV1) and DLCO, dyspnea score. Pathologic stage and type
of adjuvant therapy was recorded for patients treated with
sublobar resection. Actuarial overall survival was calculated
from the completion of therapy.
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RESULTS
Patient Characteristics
A total of 96 patients were identified with clinical stage
I NSCLC that did not receive treatment with standard sur-
gery. This represents 23% of all patients with stage I NSCLC
evaluated at our institution. Median follow-up was 30
months. All identified patients received cancer directed ther-
apy. The median age of patients was 73 years (range, 48–87).
The majority of patients were female (69%) with an Eastern
Cooperative Oncology Group performance status (ECOG
PS)  1 (69%). The distribution of patient characteristics by
treatment is shown in Table 1.
Pulmonary Function and Supplemental Oxygen
Requirement
Pretreatment pulmonary function tests were available for
32 patients undergoing sublobar resection. The median FEV1
was 1.13 liter (range, 0.76–3.35) with a median 51% of pre-
dicted FEV1 (range, 38–99%). The median carbon monoxide
diffusing capacity (DLCO) was 47% (range, 39–105%) for 22
surgery patients with available data. Pretreatment pulmonary
function tests were available in 33 radiotherapy patients with a
median FEV1 of 0.9 liter (range, 0.38–2.19 liter), and median
percentage of predicted FEV1 of 38.5% (range, 23–71%). Ra-
diotherapy patients had a worse percentage of predicted FEV1
compared with surgery patients by t test (p 0.014). DLCOwas
tested in 25 RT patients with a median value of 38% of predicted
(range, 15–82%). Few patients treated with RFA had pretreat-
ment pulmonary function testing. The entire population had a
median FEV1, percentage predicted FEV1 and DLCO of 0.98L
(range, 0.38–3.43), 46% (range, 21–99%), 42% (range, 15–
105%) respectively.
Twenty-seven patients (28%) required supplemental oxy-
gen prior to therapy: 10 surgery patients, 14 radiotherapy pa-
tients, and 3 RFA patients. The Medical Research Council
(MRC) dyspnea scores11 were obtained before treatment on all
but one patient. Surgery patients had a median MRC dyspnea
score of ‘3’ (range, 0–4). Radiotherapy patients had a median
MRC dyspnea score of ‘3’ (range, 1–4). RFA patients had a
median MRC dyspnea score of ‘1’ (range, 1–4).
Stage
Six patients had two synchronous primary neoplasms:
five in the surgery group and one in the radiation group.
Surgical patients also had a final pathologic stage postoper-
atively. In 8 (18%) of a total of 45 patients this stage was
higher than the initial clinical stage. Pathologic stage was IA
in 33 neoplasms, IB in 10 patients, IIB in 1 patient, IIIB in 5
patients, and IV in 1 patient.
Patients given primary radiotherapy had clinical stage
IA for 27 neoplasms and IB for 13. Patients who underwent
RFA had clinical stage IA for 10 neoplasms and IB for 2.
Treatment
Surgery
A total of 45 patients had primary surgery on 50
primary malignancies. Wedge resection with an open tech-
nique was performed on 27 patients. Video assisted thoras-
copic surgery wedge resection was performed on 16 patients.
One patient each underwent video assisted thorascopic sur-
gery segmentectomy and open segmentectomy. Sixteen sur-
gical patients had close or positive margins of resection, and
nine of these patients underwent postoperative radiotherapy.
Two patients with negative margins also underwent postop-
erative radiotherapy. Two patients received postoperative
chemotherapy.
Radiotherapy
Patients were simulated using a dedicated CT simula-
tor. Immobilization was accomplished with a Vac-Lok
(Civco, Kalona, Iowa) device and a wingboard. All primary
radiotherapy plans used a three-dimensional conformal tech-
nique treated with 6–18 MV photons. The gross tumor
volume was defined as the volume of the primary lesion
determined by the planning CT on lung settings. The clinical
target volume included the gross tumor volume with an
additional 0.5 to 1 cm margin. The planning target volume
expansion was determined by tumor motion as visualized
under fluoroscopy. Planning target volume size ranged from
9 to 101.5 cm3 with a median of 36.9 cm3. Mean lung dose
had a median value of 10.6 Gy (range, 3.0–28.8 Gy). The
median percent of total lung volume receiving 20 Gy or more
(V20) was 15.5% (range, 8–30%).
Two patients had concurrent chemotherapy with both
receiving weekly carboplatin and paclitaxel. No neoadjuvant
or adjuvant chemotherapy was administered. Median dose
was 70 Gy (range, 60–75 Gy), and the median daily fraction
size was 2.5 Gy (range, 2.0–4.11 Gy). Target volumes were
generated about the primary lesion and clinically uninvolved
regional lymph nodes were not intentionally irradiated.
RFA
RFA cases were performed under conscious sedation.
Multitined, monopolar LeVeen Needle-Electrodes (Boston
Scientific, Natick, MA) were placed percutaneously using CT
guidance. The treatment volume was the lesion with an
additional 5 mm margin. Tissue impedance was measured to
guide treatment time. Technical success was achieved in all
cases. Immediate postprocedure CT of the chest and a chest
radiograph at 2 hours were taken to observe for pneumotho-
rax. All patients were treated in a single session. No patients
receiving RFA underwent adjuvant chemotherapy.
TABLE 1. Patient Characteristics
LR RT RFA All Patients
n 45 39 12 96
Male/female 13/32 13/26 4/8 30/66
Med age 70.5 73 75 73
ECOG PS 0/1/2 18/24/2 1/33/5 5/7/0 24/64/7
Pts requiring O2 22% 33% 25% 28%
Median FEV1 (liter) 1.11 0.87 1.26 1.13
Median DLCO 46% 38% 48% 47%
LR, limited resection; RT, radiotherapy; RFA, radiofrequency ablation; FEV1,
forced expiratory volume in 1 second; DLCO, carbon monoxide diffusing capacity;
ECOG PS, Eastern Cooperative Oncology Group performance status.
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Outcomes
Overall Survival
Survival data were available for 91 of 96 patients.
Results are summarized by treatment modality in Table 2.
Kaplan-Meier estimates were used to calculate overall sur-
vival and local control rates. The median survival of the
entire population was 41 months, and 35 patients died. Thirty
of 40 evaluable surgical patients remain alive. Nineteen of 39
radiotherapy patients and 6 of 12 RFA patients died. The
actuarial 3-year survival for patients treated with limited
resection was 62.7% and median survival was not reached.
The actuarial 3-year survival for patients treated with radio-
therapy was 55.0% and median survival was 38 months. Too
few patients received RFA to analyze survival data. Figure 1
portrays the estimate of overall survival over time for the
entire cohort while Figure 2 portrays these estimates for the
surgery and radiation groups.
The influence of pretreatment variables on patient sur-
vival was examined using a multivariate analysis with mo-
dality of therapy (surgery versus RT), age, ECOG PS, and
pretreatment FEV1 taken as separate covariates. Cox propor-
tional hazard regression was used to calculate hazard ratios
(HR). Surgery versus RT yielded an HR of 1.24 (95% CI:
0.44–3.48). Age yielded an HR of 1.007 (95% CI: 0.958–
1.060). FEV1 yielded an HR of 1.029 (95% CI: 0.469–2.259),
and ECOG PS yielded an HR of 1.927 (95% CI: 0.681–
5.453).
Patterns of Failure
In the entire cohort, there were 90 patients for which
information on recurrences was available. Routine radio-
graphic surveillance typically consisted of CT scans of the
chest at 1.5, 3, 6, and 12 months for the first year following
primary therapy. Thereafter, CT was used every 6 months for
an additional 4 years. Local failure was defined using the
longest diameter of the primary lesion. The reference value was
the smallest value of the longest diameter since the beginning of
treatment. An increase in longest diameter of 20% or greater
over this reference was defined as local failure. There were 14
local failures, 10 nodal recurrences, and 20 distant metastases.
Among surgery patients, tumor relapse was documented in 14 of
40 evaluable patients, including 9 distant metastases, 7 local
recurrences, and 5 regional failures. Seven patients had multi-
ple sites of recurrence. Among radiotherapy patients, tumor
relapse was documented in 11 cases of 38 evaluable patients,
including 7 distant metastases, 5 local recurrences, and 4
regional failures. Four patients had multiple sites of recur-
rence. Among RFA patients, 12 were evaluable for sites of
relapse. Four patients developed distant metastases and one
patient had a documented local failure. Figure 3 portrays the
Kaplan-Meier estimate of progression free survival over time
for the entire cohort.
Treatment-Related Complications
There was only one reported severe surgical complica-
tion, a case of subcutaneous emphysema which occurred in a
patient who had open wedge resection of two primary lesions
in the right upper and right lower lobes. Two patients in the
radiotherapy group developed grade 3 to 4 radiation pneu-
monitis, and both of these patients had received concurrent
FIGURE 1. Kaplan-Meier estimate of over-
all survival.
TABLE 2. Outcome
Entire Cohort
(n  91
Evaluable)
RT (n  39
Evaluable)
LR (n  40
Evaluable)
3 yr survival 61.5% 55.0% 62.7%
Median survival 41 mo 38 mo Not reached
3 yr local control 79.4% 77.9% 76.3%
RT, radiotherapy; LR, limited resection.
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chemotherapy during radiotherapy. There were three reported
cases of pneumothorax requiring therapy among RFA pa-
tients.
Salvage
Two patients among all studied patients received sal-
vage therapy after local relapse. One patient had salvage
radiotherapy 67.5 Gy to treat relapse after open wedge resec-
tion. This patient had subsequent further progression of
disease. One patient had salvage RFA for local relapse after
primary radiation to 70 Gy. This patient developed distant
metastases and died of disease.
DISCUSSION
Tobacco use and age, major risk factors for NSCLC,
are also implicated in other chronic diseases such as coronary
artery disease and chronic obstructive pulmonary disease.
Accordingly, many patients with stage I NSCLC are not
suitable candidates for standard anatomic resection (e.g.,
lobectomy) due to the presence of these or other comorbid
conditions. Data from the SEER suggest that as many 31% of all
patients with localized NSCLC do not undergo lobectomy.12 In
our own institutional experience, 23% of all patients with
clinical stage I NSCLC received alternative therapies due to
high-risk features.
FIGURE 2. Kaplan-Meier estimate of sur-
vival by treatment group.
FIGURE 3. Kaplan-Meier estimate of pro-
gression free survival.
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The benefit of therapy has not been tested in phase III
trials in the high-risk population, and the presence of severe
medical comorbidity has led many physicians to adopt a
nihilistic approach. Moreover, concerns have been raised
about the potential toxic effects of definitive treatment such
as high dose radiotherapy or limited surgery in patients with
poor pulmonary reserve. However, the outcomes for patients
with early stage NSCLC that do not receive cancer directed
therapy are poor. For example, Raz et al.9 reviewed the
California Cancer Center registry and reported a median
survival of only 9 months in 1432 patients with stage I
NSCLC that received no initial treatment. Other reports
confirm poor survival in this patient population when cancer
directed therapy is withheld, and suggest that the majority of
patients die of lung cancer despite having substantial comor-
bid medical illness.13 Additional evidence from prospectively
collected data in a screening context shows that even small
lung cancers, left untreated, have a very poor outcome.14
Our experience emphasizes that all patients with stage
I NSCLC should be carefully assessed for consideration of
definitive therapy, and is unique in evaluating patient out-
comes after intervention with contemporary treatment alter-
natives such as three-dimensional conformal radiotherapy,
video-assisted thorascopic wedge resection and RFA. The
expectation is that these advanced treatment techniques may
lead to an improved therapeutic ratio by improving tumor
control and/or reducing the toxic effects of therapy. The
outcomes in our study are encouraging with 3-year survival
55 to 60% regardless of the therapy employed.
As with any retrospective study, caution should be used
in generalizing the results as patient selection can be an
important factor in single institution retrospective studies. For
example, in contrast to most studies, our patient population
was predominantly female. Nevertheless, the majority of our
population had substantial comorbid medical illness, and this
is reflected in part by the high percentage of patients already
requiring supplemental oxygen prior to therapy. It has been
our general policy to offer treatment to all patients with
documented NSCLC regardless of medical comorbidity, and
there was not a cohort of patients with stage I NSCLC that did
not receive therapy.
One point of note is the local control rate for radiother-
apy which was 77.9% at 3 years. This compares favorably to
historical data at approximately 50%.15 Likely this is due to
the routine use at our institution of 70 Gy as a total dose in an
accelerated and hypofractionated fashion, which has been
prospectively proven to be safe and efficacious.16 Sibley,15 in
his review of observational series in this setting, notes a
similar dose response for total doses70 Gy. Any difference
may also be due to chance given the limited sample size of
our radiotherapy group.
The present study was not designed to test the relative
merits of alternate treatments for patients with high-risk
NSCLC. The multivariate analysis of the effect of treatment
modality and pretreatment variables on survival found that
the 95% confidence intervals for all HR crossed unity. This
likely resulted from the limited sample size and retrospective
nature of this study as patient selection is obviously a critical
issue in the decision to proceed with operative (e.g., wedge
resection) versus nonoperative therapy (e.g., radiotherapy or
RFA). Nevertheless, our results suggest that the specific
treatment option employed may not be critical, as outcomes
were encouraging with limited resection, conformal radio-
therapy and RFA. Recently completed and ongoing prospec-
tive studies should help define the efficacy and toxic effects
of several treatment alternatives in this important patient
population.
CONCLUSION
Medical inoperability does not necessarily correspond
to poor survival in patients with early stage NSCLC. The
relative merits of alternate treatment approaches remain to be
defined, but this experience emphasizes the importance of
considering definitive therapy for all patients with early stage
NSCLC.
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